Partnership between Paradigm4 and Alnylam accelerates drug target discovery
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets…
October 26, 2022 - 3 minutes
Alnylam
The coming of age story of RNAi technology
The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development.…
July 22, 2022 - 7 minutes
The COVID-19 pandemic has driven RNA therapeutics into the mainstream
As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit…
July 4, 2022 - 8 minutes
Alnylam Gets Second RNAi Drug Approval from EMA
US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug -- for treatment…
March 3, 2020 - 2 minutes
Novartis Enters RNA Therapeutics with Medicines Company Merger
Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to…
November 25, 2019 - 3 minutes
UK Biotech Settles Lawsuit on the First RNAi Drug
Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal…
December 11, 2018 - 3 minutes
How is Biotech Innovating to Treat Hemophilia? Let’s Review
Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to…
February 13, 2018 - 7 minutes
Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017
Now that we've got the bad news out of the way, we're here to spread…
December 18, 2017 - 9 minutes
Infographic: What is RNAi Therapy? Targeting the Untargetable
Everything you need to know about what RNAi is, how it works and how it…
November 22, 2017 - 2 minutes
RNA as a Therapy: Reviewing the Future Generation of Therapeutics
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA?…
September 19, 2017 - 9 minutes
Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi
Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi…
July 10, 2017 - 3 minutes
RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia
Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy…
November 15, 2016 - 2 minutes
